Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Incyte Corp (NASDAQ: INCY) closed at $86.64 up 1.40% from its previous closing price of $85.44. In other words, the price has increased by $1.40 from its previous closing price. On the day, 1.35 million shares were traded. INCY stock price reached its highest trading level at $86.69 during the session, while it also had its lowest trading level at $85.06.
Ratios:
For a deeper understanding of Incyte Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.66. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 01, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $90. Stifel Upgraded its Hold to Buy on June 16, 2025, while the target price for the stock was maintained at $107.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Denton Sheila A. sold 598 shares for $84.97 per share. The transaction valued at 50,812 led to the insider holds 33,200 shares of the business.
SHEILA DENTON bought 598 shares of INCY for $50,812 on Sep 02 ’25. On Aug 15 ’25, another insider, Denton Sheila A., who serves as the EVP & General Counsel of the company, sold 277 shares for $86.81 each. As a result, the insider received 24,046 and left with 33,200 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 16918712320 and an Enterprise Value of 14539395072. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.70, and their Forward P/E ratio for the next fiscal year is 12.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.69 while its Price-to-Book (P/B) ratio in mrq is 4.03. Its current Enterprise Value per Revenue stands at 3.171 whereas that against EBITDA is 13.705.
Stock Price History:
The Beta on a monthly basis for INCY is 0.74, which has changed by 0.39158368 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $87.99, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 13.18%, while the 200-Day Moving Average is calculated to be 24.19%.
Shares Statistics:
For the past three months, INCY has traded an average of 1.80M shares per day and 1708270 over the past ten days. A total of 194.12M shares are outstanding, with a floating share count of 192.94M. Insiders hold about 1.20% of the company’s shares, while institutions hold 102.39% stake in the company. Shares short for INCY as of 1755216000 were 9603401 with a Short Ratio of 5.33, compared to 1752537600 on 7118612. Therefore, it implies a Short% of Shares Outstanding of 9603401 and a Short% of Float of 6.950000000000001.
Earnings Estimates
The current rating of Incyte Corp (INCY) reflects the combined expertise of 15.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $1.79, with high estimates of $2.2 and low estimates of $1.46.
Analysts are recommending an EPS of between $7.1 and $4.84 for the fiscal current year, implying an average EPS of $6.08. EPS for the following year is $7.06, with 19.0 analysts recommending between $9.22 and $3.42.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $1.26B this quarter.It ranges from a high estimate of $1.29B to a low estimate of $1.21B. As of the current estimate, Incyte Corp’s year-ago sales were $1.14BFor the next quarter, 18 analysts are estimating revenue of $1.32B. There is a high estimate of $1.41B for the next quarter, whereas the lowest estimate is $1.27B.
A total of 20 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.92B, while the lowest revenue estimate was $4.77B, resulting in an average revenue estimate of $4.84B. In the same quarter a year ago, actual revenue was $4.24BBased on 20 analysts’ estimates, the company’s revenue will be $5.35B in the next fiscal year. The high estimate is $5.65B and the low estimate is $5.12B.
